Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL275279 | 0.85 | SMN1; SMN2 (0.48) | KMT2ASMN1; SMN2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1427169 | 0.82 | — | — | |
| SCHEMBL28079608 | 0.81 | KMT2A (0.41) | KMT2ASMN1; SMN2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL28548490 | 0.79 | SLC1A3 (0.34) | KMT2ASLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL170213 | 0.79 | SLC1A3 (0.34) | KMT2ASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7715983 | 0.79 | KMT2A (0.40) | KMT2ASMN1; SMN2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL2727651 | 0.78 | SMN1; SMN2 (0.42) | KMT2ASMN1; SMN2CA14CA12ALDH1A1 | |
| SCHEMBL4755149 | 0.77 | ALDH1A1 (0.42) | KMT2ASMN1; SMN2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL27968726 | 0.77 | TSHR (0.40) | KMT2ASMN1; SMN2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL11685073 | 0.77 | SLC1A3 (0.33) | KMT2ASLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108698992-B | 2-cyanoisoindoline derivatives for the treatment of cancer | 特殊治疗有限公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3429994-B1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LTD (GB) | 2021-06-16 | — | — | EP | disclosed |
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-16 | — | — | US | disclosed |
| EP-3429994-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | Mission Therapeutics Limited (GB) | 2019-01-23 | — | — | EP | disclosed |
| US-20190010122-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2019-01-10 | — | — | US | disclosed |
| CN-108698992-A | 2- cyano isoindoline derivatives for treating cancer | 特殊治疗有限公司 | 2018-10-23 | — | — | CN | disclosed |
| WO-2017158388-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2017-09-21 | — | — | WO | disclosed |
| US-8765766-B2 | Pyrimidine derivatives which are antagonists of the vitronectin receptor | GALAPAGOS NV (BE) | 2014-07-01 | — | — | US | disclosed |
| EP-2519102-A2 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | Development Center For Biotechnology (TW) | 2012-11-07 | — | — | EP | disclosed |
| US-20120115883-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONISTS OF THE VITRONECTIN RECEPTOR | GALAPAGOS SAS | 2012-05-10 | — | — | US | disclosed |
| US-20040210079-A1 | N-acylamino benzyl ether derivatives | JOLIDON SYNESE | 2004-10-21 | — | — | US | disclosed |
| US-6762320-B2 | MONOAMINE OXIDASE B INHIBITORS; ALZHEIMER'S DISEASE, SENILE DEMENTIA | HOFFMAN-LA ROCHE INC. | 2004-07-13 | — | — | US | disclosed |
| US-20030232883-A1 | N-acylamino benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2003-12-18 | — | — | US | disclosed |
| US-6613934-B1 | Enzymatic partial hydrolysis of a diester of malonic acid | DEGUSSA AG (DE) | 2003-09-02 | — | — | US | disclosed |
| EP-0812819-B1 | Enantiomer-enriched tertiary hydrocarbonrest-substituted malonic acid ester and the preparation | DEGUSSA (DE) | 2001-11-28 | — | — | EP | disclosed |
| EP-0812819-A2 | Enantiomer-enriched tertiary hydrocarbonrest-substituted malonic acid ester and the preparation | HÜLS AKTIENGESELLSCHAFT (DE) | 1997-12-17 | — | — | EP | disclosed |
| US-5637613-A | ANTITUMOR AGENT; IMMUNOSUPPRESSANTS | FOURNIER INDUSTRIE ET SANTE (FR) | 1997-06-10 | — | — | US | disclosed |
| EP-0444482-B1 | Oxetanones | HOFFMANN LA ROCHE (CH) | 1996-01-17 | — | — | EP | disclosed |
| US-5476870-A | Immunosuppressants | FOURNIER INDUSTRIE ET SANTE (FR) | 1995-12-19 | — | — | US | disclosed |
| EP-0444482-A2 | Oxetanones | F. HOFFMANN-LA ROCHE AG (CH) | 1991-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190010122-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | USP7, USP47, USP2 | KMT2A 1292/4885SMN1; SMN2 4184/4885SLC1A3 4230/4885 |
| US-20030232883-A1 | N-acylamino benzyl ether derivatives | MAOB, MAOA, AOC2 | KMT2A 309/4885SMN1; SMN2 933/4885SLC1A3 1652/4885 |
| US-20040210079-A1 | N-acylamino benzyl ether derivatives | MAOB, MAOA, CBR1 | KMT2A 363/4885SMN1; SMN2 950/4885SLC1A3 1782/4885 |
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | USP7, USP47, USP2 | KMT2A 1292/4885SMN1; SMN2 4184/4885SLC1A3 4230/4885 |
| US-20120115883-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONISTS OF THE VITRONECTIN RECEPTOR | P2RY1, P2RY2, P2RX5 | KMT2A 4684/4885SMN1; SMN2 3997/4885SLC1A3 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.